An Early Phase 1 interventional study of Huperzine A and Placebo in Cognitive Enhancement During Exercise, sponsored by St. Louis University. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-31.
Sponsored by St. Louis University · Early Phase 1, Interventional, and Other
Among 2,858 studies in Motor Activity with a site in United States — 423 open to participants now, 564 under way, 9 of them phase 3. Motor Activity · United States.
Among the 2,858 studies in Motor Activity with a site in United States, this one is the 2,281st largest by enrollment of the 2,605 interventional ones that give a count, is one of 170 that started in 2018, is one of 103 in phase 1, and was the 1,420th registered.
9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.
Browse Motor Activity studies →423 of the 2,858 studies in Motor Activity with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
University of Pennsylvania · Sites in United States
San Diego State University · Sites in United States
Beth Israel Deaconess Medical Center · Sites in United States
University of Arizona · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,201 Motor Activity studies recruiting now, 517 (43%) set no upper age limit and 535 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,858 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 139 · Phase 2 180 · Phase 3 83 · Phase 4 33
First in 1977; this study’s year is marked. 170 started in 2018.
This study's enrollment of 15 is below the median of 60 across 8,388 interventional studies indexed under Motor Activity.
Median enrollment 55 across the 2,605 interventional studies, 67 across the 240 observational. Of the 2,100 that completed or were terminated, 539 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 2,858 have an industry lead sponsor. The 10 most frequent:
St. Louis University is the lead sponsor of 156 studies on the registry; 17 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
St. Louis University has 4 studies filed under Motor Activity — fewer than ten, so there is no comparison to draw.
210 of the studies in Motor Activity with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07298915Phase 3University of VirginiaThe Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | 2026-12 |
| NCT06159335Phase 3University of Wisconsin, Madison18F-FLUC PET/MR in Patients With Brain Mets | 2027-06 |
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT06290713University of FloridaVasodilator and Exercise Study for DMD (VASO-REx) | 2026-11 |
Among the 2,858 studies in Motor Activity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the effects of acute huperzine A ingestion prior to exercise on cognitive function and perceived effort in exercise-trained individuals. Huperzine A has shown the ability to improve cognitive function in dementia patients, and is currently marketed as a cognitive enhancing supplement. Study participants will receive either huperzine A or placebo during the first experimental session, and will receive the other substance during the second session.
Huperzine A improves cognitive function by inhibiting the enzyme acetylcholinesterase. This enzyme is responsible for the degradation of the neurotransmitter acetylcholine. inhibition of acetylcholinesterase may allow for greater availability of acetylcholine, which may allow for better nerve conduction and therefore enhanced cognitive function and possibly muscular contraction.
Huperzine A (200 mcg, Swanson®, Fargo, North Dakota) and placebo capsules will be administered in a single oral dose. The dose of Huperzine A to be used is comparable to previous research (Xu et al, 2011). Placebo capsules will consist of rice flour. The participants will ingest the capsules with 250 mL of water 30-45 minutes before exercise is initiated.
A paired-sample t-test with alpha set to p ≤ 0.05 for statistical significance will be used to analyze the data. Outcomes measured during the first and second experimental sessions will be compared to each other. The participants will be compared to themselves during previous sessions, so a paired sample t-test will be used to calculate the difference between the sessions. Data will be presented as means ± SE. Data analyses will be performed with Microsoft Excel; and other analyses may be performed as needed to gain further insights about the data.
A statistical power analysis was performed (G*Power software, version 3.1.5, University of Kiel, University of Dusseldorf, and University of Mannheim, 157 Germany) based on the following inputs: two-tailed paired t-test, alpha=0.05, desired power=0.80, sample size=15 subjects. The results indicated that a standardized effect size of 0.78 (i.e. large effect) will be detectable. As many as 20 subjects will be recruited and enrolled to ensure that complete data on 15 subjects are available in the event of screen fails and dropouts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Huperzine A will be provided in the form of a single capsule for oral ingestion.
Other: Huperzine A
Placebo will be provided in the form of a single capsule for oral ingestion.
Other: Placebo
During one of the two experimental sessions, participants will be given huperzine A.
During one of the two experimental sessions, participants will be given a placebo.
Digit span
Digit span will be used as a measure of working memory. During a period of two minutes, the participants will be presented with a series of digits at a rate of one digit per second, and will be required to to repeat them verbatim. If they succeed, they will be presented with a longer series by one digit. The longest series that they are able to correctly repeat will be the number of their score (i.e. if they are able to repeat a series of 7 digits, their score will be 7).
Time frame: This test will be implemented during a 2 minute window during the last 10 minutes of endurance exercise.
Verbal Fluency
Verbal fluency will be used as a measure of executive function. Participants will be instructed to generate words beginning with F, A, S, B, H, or R. Each participant will be randomly assigned a different letter at each session.
Time frame: This test will be implemented during a 1 minute window during the last 10 minutes of endurance exercise.
Category Fluency
Category fluency will be used as a measure of executive function. Participants will be instructed to produce as many words as they can for a particular category within one minute. Each participant will be randomly assigned a different category at each session.
Time frame: This test will be implemented during a 1 minute window during the last 10 minutes of endurance exercise.
Stroop Effect Test
The Stroop effect test will be used as a measure of information processing. Participants will be exposed to color names printed in an ink color that does not match the color name. They will be instructed to name the color of the ink and to ignore the color name.
Time frame: This test will be implemented during a 2 minute window during the last 10 minutes of endurance exercise.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2018 to primary completion in Apr 2018, 2 months.
Of 73 non-industry phase 1 interventional studies under Motor Activity, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's 2 months is below that.
Counting every sponsor, half of 75 studies reached it within 20 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.